Abstract:HomeCirculation ResearchVol. 118, No. 12Chinese Basic Cardiovascular Research in Transition Free AccessResearch ArticlePDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessResearch ArticlePDF/EPUBChinese Basic Cardiovascular Research in Transition Xinyang Hu, Huang-Tian Yang, Yuangui Zhu, Jian’an Wang and Erdan Dong Xinyang HuXinyang Hu From the Department of Cardiology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China (X.H., J.W.); Key Laboratory of Stem Cell Biology and Laboratory of Molecular Cardiology, Institute of Health Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences & Shanghai Jiao Tong University School of Medicine, Shanghai, China (H.-T.Y.); Department of Health Sciences, National Natural Science Foundation of China, Beijing, China (Y.Z., E.D.). Search for more papers by this author , Huang-Tian YangHuang-Tian Yang From the Department of Cardiology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China (X.H., J.W.); Key Laboratory of Stem Cell Biology and Laboratory of Molecular Cardiology, Institute of Health Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences & Shanghai Jiao Tong University School of Medicine, Shanghai, China (H.-T.Y.); Department of Health Sciences, National Natural Science Foundation of China, Beijing, China (Y.Z., E.D.). Search for more papers by this author , Yuangui ZhuYuangui Zhu From the Department of Cardiology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China (X.H., J.W.); Key Laboratory of Stem Cell Biology and Laboratory of Molecular Cardiology, Institute of Health Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences & Shanghai Jiao Tong University School of Medicine, Shanghai, China (H.-T.Y.); Department of Health Sciences, National Natural Science Foundation of China, Beijing, China (Y.Z., E.D.). Search for more papers by this author , Jian’an WangJian’an Wang From the Department of Cardiology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China (X.H., J.W.); Key Laboratory of Stem Cell Biology and Laboratory of Molecular Cardiology, Institute of Health Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences & Shanghai Jiao Tong University School of Medicine, Shanghai, China (H.-T.Y.); Department of Health Sciences, National Natural Science Foundation of China, Beijing, China (Y.Z., E.D.). Search for more papers by this author and Erdan DongErdan Dong From the Department of Cardiology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China (X.H., J.W.); Key Laboratory of Stem Cell Biology and Laboratory of Molecular Cardiology, Institute of Health Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences & Shanghai Jiao Tong University School of Medicine, Shanghai, China (H.-T.Y.); Department of Health Sciences, National Natural Science Foundation of China, Beijing, China (Y.Z., E.D.). Search for more papers by this author Originally published10 Jun 2016https://doi.org/10.1161/CIRCRESAHA.116.308063Circulation Research. 2016;118:1876–1879Basic cardiovascular research in China has developed dramatically during the last decade but faces unique challenges especially to improve quality and impact. In this viewpoint, we analyzed the causes that have contributed to such accelerated research activity in the cardiovascular field and discuss ways to deal with the challenges.Cardiovascular disease (CVD) is the major cause of morbidity and mortality in China presenting rapidly evolving public health and economic burdens.1 China recognizes the need to develop a modern and optimized medical care system that includes cutting edge translational biomedical research to target CVD as a fundamental ingredient. Rapidly growing financial support from government sources has fueled quantum increases in scientific output of cardiovascular basic research in China during the past decade. However, China still faces significant challenges to improve the efficiency, quality, and impact of such research, as well as to effectively address the prevention and treatment of CVD.Chinese Cardiovascular Basic Research OutputIn parallel with China’s elevation to the world’s second largest economy, scientific publications in cardiovascular research (CVR) also achieved remarkable growth. During 2006 to 2015, cardiovascular basic research publications with Chinese corresponding authors had the following characteristics (data were restricted to research articles from peer-reviewed and non–open-access journals and provided by the Shanghai Information Center for Life Sciences of the Chinese Academy of Science [CAS] based on the analysis of database of Web of Science-Science Citation Index Expanded): (1) The publications from Chinese corresponding authors in 2015 was 4.2-fold of that in 2006 (Figure 1A, left axis); (2) the percent global contribution of Chinese publications increased from 2.76% in 2006 to 9.83% in 2015 (Figure 1A, right axis). Consistent with this, the proportion of publications from China ranked 9 in 2006 and 2 in 2012 and subsequent years. To further characterize the publication dynamics, we analyzed the productivity of the articles published in 8 representative CVR journals, including Am J Physiol-Heart Circ Physiol, Arterioscler Thromb Vasc Biol, Basic Res Cardiol, Cardiovasc Res, Circulation, Circ Res, Hypertension, and J Mol Cell Cardiol. Chinese publications in these journals increased steadily. There were 21 publications in 2006 (0.95% total) and 103 in 2015 (6.82% total). However, the publications from the United States were much higher even in 2015 (697, 46.16%), but this has been relatively stable with no percentage growth of US contributions since 2006; and (3) among the publications, the percentage of highly cited research papers (ranking among the top 1% most cited for the field based on the Essential Science Indicators database) from China was 1.11% in 2006, 1.03% in 2011, and 2.34% in 2015 by September/October (Figure 1B). These data confirm a major and continuing increase in scientific contributions from Chinese scientists to the global field of CVR. Noteworthily, although the academic impact of Chinese publications, reflected by highly cited papers, during the past 10 years has been significantly enhanced, it does not match the exceptional growth in total publications.Download figureDownload PowerPointFigure. Publications and grants from the National Natural Science Foundation of China (NSFC) during 2006 to 2015. (A and B) Number and contribution of publications and highly cited original research papers in the field of cardiovascular research in non–open-access journals by corresponding authors from China during 2006 to 2015 based on Web of Science Database Science Citation Index Expanded up to March 4, 2016. The data were provided by the Shanghai Information Center for Life Sciences of the CAS. (A) The number (red curve) and percentage (blue curve) of publications. (B) The number (red curve) and percentage (blue curve) of highly cited research papers (ranking among the 4372 of top 1% most cited papers out of 400 384 total ones in the field based on the Essential Science Indicators database up to September/October of 2015. (C) Grant number and (D) funding amount from NSFC for the cardiovascular research from 2006 to 2015. The data were provided by NSFC of China.Intellectual property, filed and issued patents represent another measure of scientific output and innovation. On the basis of the analysis of database from Dialog Innography by the Shanghai Information Center for Life Sciences of the CAS, there were totally 19 112 disclosed patents from China in the field of CVR during 2006 to 2015, representing 16% of the world total in 2006 and 31% in 2015. This ranks Chinese new patents as second in the world for 2015. However, in terms of Patent Cooperation Treaty patents in the cardiovascular area, China only contributed 1% of the world total in 2006 and 3% in 2015, with ninth rank globally. These analyses confirm the rapid increase in quantity but not necessarily quality of CVR scientific output in China. To improve quality and impact, the Chinese research culture needs to change to become more focused on original, innovative, and high-risk, high-gain/impact research.Funding RolesStable increases of government investment have played a critical role in the rapid growth of Chinese CVR. The National Natural Science Foundation of China (NSFC) and Chinese Ministry of Science and Technology (MOST) are the 2 major funding agencies in China for cardiovascular basic research. Additionally, the Ministry of Education, National Health and Family Planning Commission, CAS as well as local government have also increased funding for CVR. For example, the funding by the NSFC for CVR increased to 418.5 million Ren Min Bi (RMB) in 2015 from 48.5 million RMB in 2006. In particular, the total funding number for CVR from NFSC significantly increased in recent 5 years (2011–2015) compared with the period of 2006 to 2010 (Figure 1C), concomitantly with an increase of funding to 1718.4 million RMB during 2011 to 2015 from 438.4 million RMB during 2006 to 2010 (Figure 1D).Government funding plays a leading role in orientating output of research areas. The National Basic Research Program of China (973 Program) managed by the Chinese Ministry of Science and Technology is one of the major focused funding sources for CVR. Since 2010, the 973 Program granted 15 research projects in the cardiovascular area including circulating microRNAs, mitochondrial dysfunction in heart failure, pathogenic mechanisms of atherosclerosis and arrhythmia, vascular senescence, regulation of heart development and deficiency, and stem cells in heart failure therapy. Meanwhile, to answer the call for improving public health nationwide and promoting biomedical translational research, NSFC launched the Department of Health Sciences in 2009 to support medical science relevant basic researches associated with disease prevention, control, and treatment in China. The Department of Health Science initiated a Major Research Program in 2013 with 200 million RMB for steady and continuous support to explore the mechanisms of vascular homeostasis and remodeling.2 As a result, the number of publications on vascular smooth muscle cells, atherosclerosis, and microRNA has significantly increased.3 Some important pioneering breakthroughs in basic translational research are attributed to the increased and targeted funding, for example, it was first reported by Chinese scientists that the coronary artery is derived from endocardium4,5; muscle-specific mitsugumin 53 acts as a primary component of cardiac ischemic preconditioning and critically contributes to cardiac diabetic cardiomyopathy via regulating fatty acid metabolism6–8; endothelial function is improved by dietary capsaicin through activating the transient receptor potential vanilloid9,10; and consumption of spicy foods is related to a reduced risk of mortality because of ischemic heart diseases.11Furthermore, government funding contributes critically to promote the establishment of research platform and innovative as well as risk-taking research. Major research centers and key laboratories at national and local levels were established under the financial support of the government, with a goal to develop CVR excellence. For example, in 2011, China’s National Center for Cardiovascular Diseases was established based in Fuwai Hospital, and in 2013, the government initiated 2 National Clinical Research Centers for CVR in Fuwai hospital and Anzhen hospital. In addition, the General Program of NSFC encourages researchers at various career stages to freely select topics in cardiovascular areas. During the past 10 years, among the total research-related program funding of NSFC in CVR, 83.78% was for the General Program. These incentives are important to help researchers to develop a more focused specific scheme with a high potential impact, translational and clinical values. For example, with the support of the General Program of NSFC, Li’s group12 revealed a novel function and regulatory mechanisms of interferon regulatory factor 8 in cardiac remodeling.Although the rapid increase of government investment has brought a robust increase in the output of CVR, the funding is still not appropriately in line with the rapid development of the national Gross Domestic Product, growing aging population, and the urgent health needs of patients with CVD. To continue improvement of the quality and impact of Chinese cardiovascular science and promote translational research and precision therapy, a continuing increase of investment from government, including the central and local governmental agencies, in this area is imperative to ensure high-quality research with global impact. In addition, the financial support from nongovernment sources needs to be energetically developed. This needs to be supported and guided at least in part by the central or local governments to substantially increase private sector initiatives to develop innovative research programs and recruit and retain talents, by integrating government, clinical and private sector resources, and platforms.Researcher RolesResearchers are at the core of transition in the output of Chinese cardiovascular basic research. Many active Chinese researchers who obtained overseas study and work experience have returned to China during the past 20 years under the support of governmental and institute talent programs, such as One Hundred Talents Program initiated in 1994 by the CAS, Yangtse River Scholars Program by the Ministry of Education of China from 1998, and more recently, Thousand Young Talents Program launched in 2011 by the central government. Besides attracting the elite researchers from recognized universities and institutes globally, a critical issue is to develop and retain talented researchers. NSFC is playing a leading role in this aspect by launching specific Talent Program that targets researchers at various career stages, such as the Distinguished Young Scholars Program for well-established senior researchers, the Excellent Young Scholars Program for young researchers starting their own programs, and the Young Fund for young investigators just starting independent research. In 2006, NSFC funded only 53 cardiovascular researchers with 13.56 million RMB, whereas in 2015, it increased to 337 with 125.22 million RMB. The funding in 2015 was 9.23-fold of that in 2006 (Figure 1D). This major transition in the support for talents helps to foster and retain outstanding researchers in this field and especially benefits the development of young researchers. Until now, a total of 25 young scholars in the field of CVR were supported by NSFC for Distinguished Young Scholars Program. They all conducted creative researches and grew up as outstanding academic leaders in the forefront of clinical and basic research in CVR and made important contribution to the development of CVR in China.Meanwhile, more highly motivated and talented MS and PhD students as well as young researchers are involved in CVR. As a result, the base of cardiovascular researchers in China significantly increased during the past 10 years, for example, membership in the China Section of the International Society for Heart Research increased from 289 in 2006 to 1140 in 2015 (provided by the China Section of International Society for Heart Research). However, the evolving base and capacity of Chinese cardiovascular researchers do not adequately meet the urgent need for reducing the CVD risk. The world-class academic leaders, as well as highly talented and experienced research leaders, need to be fostered. Moreover, a stronger funding support to postdoctoral scientists, and training for researchers, including principal investigators at all stages of careers, as well as the technicians, are needed. In addition, evaluations for faculty recruitment and scientific performance needs to involve broader assessment mechanisms to include research productivity–based global relevance as well as scientific quality rather than simply counting the publication number or impact factors as is currently practiced at most Chinese institutions. Furthermore, a more productive and efficient research environment needs to be fostered by increasing global competition.Cooperation RolesIncreased domestic and international cooperation, founded by NSFC and Chinese Ministry of Science and Technology, is contributing importantly to the rapid growth of output and impact of CVR. For example, NSFC increased funding for the International Cooperation Program from 1.03 million RMB in 2006 to 8.81 million RMB in 2015 (Figure 1C and 1D) and funded 15 Key International Cooperation Programs of CVR in the field of epigenetics, metabolomics, and stem cells in the past 5 years. Although most of these are still underway, some encouraging progress has already been made. For example, the researcher from Peking University collaborated with the researcher from University of London and revealed a novel molecular mechanism of vascular injury and repair.13,14 The success of domestic and international collaborations is exemplified by the increased incidence of highly cited collaborative papers during the past decade: collaborative highly cited papers increased from 0% in 2006 to 70% in 2015 (data were provided by the Shanghai Information Center for Life Sciences of CAS based on the Essential Science Indicators database). However, it is still necessary to further strengthen the relationship with the top-tier universities and institute globally and promote deeper and tighter domestic and international collaborations by sharing knowledge, facilities, and resources including scientific data and animal models. One specific and practical initiative to promote this would be to remove the barrier of authorship contribution by reforming the assessment system from assigning credit for each article solely to author(s) with first institute into a more appropriate way to recognize the contributions of all authors.In conclusion, the increased government investment in CVR during the past decade has supported a remarkable transition of Chinese cardiovascular basic research productivity that is characterized by a surge in the volume of publications but moderate relative improvement in overall quality. Global research impact still lags behind publication quantity. To deal with the rapidly expanding challenges of CVD, the research model as it applies to the Chinese situation needs to be further developed and fine-tuned. First, a clinically driven, basic, and translational research model should be developed and implemented. Second, more emphasis needs to be given to develop, expand, and validate Traditional Chinese Medicine especially as it applies to the prevention and treatment of CVD. Third, cross-discipline integration and collaboration need to be emphasized. To implement these changes and ensure growth, China needs to increase funding for CVR even more, expand the base of researchers, and improve research environments as well as support system to favor excellence and innovation. In addition, more CVR centers and key laboratories need to be established to promote integrative and collaborative CVR at the levels of basic, translational, and clinical studied and developmental pharmacology research. Communication and collaboration between basic scientists with physicians need to be closer and deeper; the government and institutes need to develop efficient mechanisms and platforms to promote the collaboration between basic scientists and physicians. These efforts will be essential to continue the growth of Chinese CVD research, align it with the overall economic growth, and develop new strategies that are so urgently needed to fight against the growing threat of CVD to the people of China.Nonstandard Abbreviations and AcronymsCASChinese Academy of ScienceCVDcardiovascular diseaseCVRcardiovascular researchNSFCNational Natural Science Foundation of ChinaRMBRen Min BiAcknowledgmentsWe thank Hongbo Jiang, Hengzhe Wang, and Kaiyun Mao from the Shanghai Information Center for Life Sciences of the Chinese Academy of Science (CAS) for the analysis of publications and patents in the field of cardiovascular research.DisclosuresNone.FootnotesThe opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.Correspondence to Erdan Dong, MD, PhD, Department of Health Sciences, National Natural Science Foundation of China, Beijing, 100085, China. E-mail [email protected]; or Jian’an Wang, MD, PhD, Department of Cardiology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310009, China. E-mail [email protected]References1. Chinese National Center for Cardiovascular Disease. Report on cardiovascular diseases in China (2014). Beijing, China: China Encyclopedia Press; 2015.Google Scholar2. Zhang YY, Dong ED. New insight into vascular homeostasis and injury-reconstruction.Sci China Life Sci. 2014; 57: 739–741CrossrefMedlineGoogle Scholar3. Gal D, Vandevelde W, Cheng H, Sipido KR. Cardiovascular research as a forum for publications from China: present, past, and future.Cardiovasc Res. 2014; 104:383–387. doi: 10.1093/cvr/cvu238.CrossrefMedlineGoogle Scholar4. Tian X, Hu T, Zhang H, He L, Huang X, Liu Q, Yu W, He L, Yang Z, Yan Y, Yang X, Zhong TP, Pu WT, Zhou B. Vessel formation. De novo formation of a distinct coronary vascular population in neonatal heart.Science. 2014; 345:90–94. doi: 10.1126/science.1251487.CrossrefMedlineGoogle Scholar5. Liu Q, Huang X, Zhang H, Tian X, He L, Yang R, Yan Y, Wang QD, Gillich A, Zhou B. c-kit(+) cells adopt vascular endothelial but not epithelial cell fates during lung maintenance and repair.Nat Med. 2015; 21:866–868. doi: 10.1038/nm.3888.CrossrefMedlineGoogle Scholar6. Cao CM, Zhang Y, Weisleder N, Ferrante C, Wang X, Lv F, Zhang Y, Song R, Hwang M, Jin L, Guo J, Peng W, Li G, Nishi M, Takeshima H, Ma J, Xiao RP. MG53 constitutes a primary determinant of cardiac ischemic preconditioning.Circulation.2010; 121:2565–2574. doi: 10.1161/CIRCULATIONAHA.110.954628.LinkGoogle Scholar7. Song R, Peng W, Zhang Y, Lv F, Wu HK, Guo J, Cao Y, Pi Y, Zhang X, Jin L, Zhang M, Jiang P, Liu F, Meng S, Zhang X, Jiang P, Cao CM, Xiao RP. Central role of E3 ubiquitin ligase MG53 in insulin resistance and metabolic disorders.Nature. 2013; 494:375–379. doi: 10.1038/nature11834.CrossrefMedlineGoogle Scholar8. Liu F, Song R, Feng Y, Guo J, Chen Y, Zhang Y, Chen T, Wang Y, Huang Y, Li CY, Cao C, Zhang Y, Hu X, Xiao RP. Upregulation of MG53 induces diabetic cardiomyopathy through transcriptional activation of peroxisome proliferation-activated receptor alpha.Circulation. 2015; 131:795–804. doi: 10.1161/CIRCULATIONAHA.114.012285.LinkGoogle Scholar9. Luo Z, Ma L, Zhao Z, He H, Yang D, Feng X, Ma S, Chen X, Zhu T, Cao T, Liu D, Nilius B, Huang Y, Yan Z, Zhu Z. TRPV1 activation improves exercise endurance and energy metabolism through PGC-1alpha upregulation in mice.Cell Research. 2012; 22:551–564. doi: 10.1038/cr.2011.205.CrossrefMedlineGoogle Scholar10. Yang D, Luo Z, Ma S, Wong WT, Ma L, Zhong J, He H, Zhao Z, Cao T, Yan Z, Liu D, Arendshorst WJ, Huang Y, Tepel M, Zhu Z. Activation of TRPV1 by dietary capsaicin improves endothelium-dependent vasorelaxation and prevents hypertension.Cell Metabolism. 2010; 12:130–141. doi: 10.1016/j.cmet.2010.05.015.CrossrefMedlineGoogle Scholar11. Lv J, Qi L, Yu C, et al; China Kadoorie Biobank Collaborative Group. Consumption of spicy foods and total and cause specific mortality: population based cohort study.BMJ. 2015; 351:h3942.CrossrefMedlineGoogle Scholar12. Jiang DS, Wei X, Zhang XF, Liu Y, Zhang Y, Chen K, Gao L, Zhou H, Zhu XH, Liu PP, Bond Lau W, Ma X, Zou Y, Zhang XD, Fan GC, Li H. IRF8 suppresses pathological cardiac remodelling by inhibiting calcineurin signaling.Nature Communication. 2014; 5:3303. doi: 10.1038/ncomms4303.CrossrefMedlineGoogle Scholar13. Kessler T, Zhang L, Liu Z, Yin X, Huang Y, Wang Y, Fu Y, Mayr M, Ge Q, Xu Q, Zhu Y, Wang X, Schmidt K, de Wit C, Erdmann J, Schunkert H, Aherrahrou Z, Kong W. ADAMTS-7 inhibits re-endothelialization of injured arteries and promotes vascular remodeling through cleavage of thrombospondin-1.Circulation. 2015; 31; 131(13):1191–1201. doi: 10.1161/CIRCULATIONAHA.114.014072LinkGoogle Scholar14. Huang Y, Xia J, Zheng J, Geng B, Liu P, Yu F, Liu B, Zhang H, Xu M, Ye P, Zhu Y, Xu Q, Wang X, Kong W. Deficiency of cartilage oligomeric matrix protein causes dilated cardiomyopathy.Basic Res Cardiol. 2013; 108(5):374. doi: 10.1007/s00395-013-0374-9.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Dong E (2022) Cell–cell crosstalk in the heart, Medical Review, 10.1515/mr-2021-0029, 1:1, (3-5), Online publication date: 26-Oct-2021., Online publication date: 1-Oct-2021. Bolli R (2019) Ten Years at the Helm of Circulation Research, Circulation Research, 124:12, (1707-1717), Online publication date: 7-Jun-2019. June 10, 2016Vol 118, Issue 12 Advertisement Article InformationMetrics © 2016 American Heart Association, Inc.https://doi.org/10.1161/CIRCRESAHA.116.308063PMID: 27283532 Originally publishedJune 10, 2016 Keywordsintellectual propertyresearchscienceanalysisChinaPDF download Advertisement SubjectsBasic Science ResearchCongenital Heart Disease

Abstract:HomeCirculation ResearchVol. 121, No. 4Basic and Translational Vascular Research in China Free AccessNewsPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessNewsPDF/EPUBBasic and Translational Vascular Research in ChinaPast, Present, and Future Wei Kong, Jie Du, Yi Zhu and Erdan Dong Wei KongWei Kong From the Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Peking University, Beijing, China (W.K.); Key Laboratory of Molecular Cardiovascular Science, Ministry of Education, Beijing, China (W.K.); Beijing Anzhen Hospital of Capital Medical University, China (J.D.); Beijing Institute of Heart, Lung, and Blood Vessel Diseases, China (J.D.); Department of Physiology and Pathophysiology, Tianjin Medical University, China. (Y.Z.); and Department of Health Sciences, National Natural Science Foundation of China, Beijing (E.D.). Search for more papers by this author , Jie DuJie Du From the Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Peking University, Beijing, China (W.K.); Key Laboratory of Molecular Cardiovascular Science, Ministry of Education, Beijing, China (W.K.); Beijing Anzhen Hospital of Capital Medical University, China (J.D.); Beijing Institute of Heart, Lung, and Blood Vessel Diseases, China (J.D.); Department of Physiology and Pathophysiology, Tianjin Medical University, China. (Y.Z.); and Department of Health Sciences, National Natural Science Foundation of China, Beijing (E.D.). Search for more papers by this author , Yi ZhuYi Zhu From the Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Peking University, Beijing, China (W.K.); Key Laboratory of Molecular Cardiovascular Science, Ministry of Education, Beijing, China (W.K.); Beijing Anzhen Hospital of Capital Medical University, China (J.D.); Beijing Institute of Heart, Lung, and Blood Vessel Diseases, China (J.D.); Department of Physiology and Pathophysiology, Tianjin Medical University, China. (Y.Z.); and Department of Health Sciences, National Natural Science Foundation of China, Beijing (E.D.). Search for more papers by this author and Erdan DongErdan Dong From the Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Peking University, Beijing, China (W.K.); Key Laboratory of Molecular Cardiovascular Science, Ministry of Education, Beijing, China (W.K.); Beijing Anzhen Hospital of Capital Medical University, China (J.D.); Beijing Institute of Heart, Lung, and Blood Vessel Diseases, China (J.D.); Department of Physiology and Pathophysiology, Tianjin Medical University, China. (Y.Z.); and Department of Health Sciences, National Natural Science Foundation of China, Beijing (E.D.). Search for more papers by this author Originally published4 Aug 2017https://doi.org/10.1161/CIRCRESAHA.117.310839Circulation Research. 2017;121:335–337In parallel with China’s economic boom, the lifestyle of Chinese people has dramatically changed. China has entered the society of aging, and the risk factors, including obesity, high-salt diet, overnutrition, sedentary behaviors, lack of physical activity, and air pollution, became more prevalent. Cardiovascular diseases have become a main threat to the public health and economic burden and the leading cause of mobility and mortality in China (Online Figure I). Here, we reviewed the history of vascular medicine, current status of research in vascular biology, medicine and funding opportunities, and challenges in future.Vascular Medicine in China: History and DevelopmentAs early as 2000 years ago, the Chinese people proposed in the Inner Canon of Huangdi that meridians are used to transport blood, working as blood vessels. After the introduction of Western medicine to China, the research on modern vascular medicine began to emerge but developed at a slow pace. In 1934, Prof Zhengang Lin from Peking Medical University published Cirrhosis of Cardiac Arteriosclerosis and Pathology of Syphilis and the Formation of Myocardial Infarction and Its Clinical Significance, which are the earliest monographs on atherosclerosis from the Chinese medical community. The first conference specifically focused on cardiovascular disease was held in 1959. In 1966, Prof Yingkai Wu, a pioneer cardiologist in China, headed the first study for the prevention and control of cardiovascular disease in Shijingshan District, Beijing, China, creating the Shougang model for China’s prevention and control of chronic diseases. After a decade of Cultural Revolution in the 1970s in China, the scientific researches and academic activities gradually recovered. Under the leadership of Prof Wu, the Chinese Society of Cardiology, a branch society affiliated to Chinese Medical Association was initiated in 1978. In 1982, a branch society of cardiovascular research in Chinese Association of Pathophysiology was established. Since then, dozens of societies of basic and clinical cardiovascular research were established in China.Nowadays, China has become one of the biggest resources for multicenter and population study worldwide. Based on the data from the clinical research registration website of National Institutes of Health (https://clinicaltrials.gov/ct2/home), there are 17 652 registered clinical trials on vascular medicine in the world currently, of which 1060 are possessed by and located in mainland China. Among these, >85% of trials are led by China. Although it accounts for only 14.3% of that by the United States (7433), it ranks first place in the number of existing clinical studies in China. However, this is still not proportional to its huge population. The representative major findings in translational research in China are listed in the Online Data Supplement.As a treasure of traditional Chinese Medicine, Chinese herb preparations (including Simiao Huoxue Decoction and Mao Dongqing) had been successfully used for the treatment of thromboangiitis obliterans since 1963. Danshen dripping pill is a widely used Chinese medicinal product in treating coronary artery disease. It has recently finished the stage III clinical trial to treat diabetic retinopathy and expected to become the first Chinese medicine preparation approved by the US Food and Drug Administration. In addition, a range of novel compound Chinese medicine has become commercially available in other Asia-Pacific countries, including Japan, Korea, and Australia, for example, Caditonic Pills, GuanXinErHao, GuanXinShuTong, Qili Qiangxin capsule, etc. A multicenter and randomized study of the effects of Qili Qiangxin capsules in patients with chronic heart failure has caught great attention of US medical field.Challenges of Vascular Biology Research in ChinaAccording to the Report on Cardiovascular Diseases in China (2015), cardiovascular and cerebrovascular diseases become the leading cause of death in China (Online Figure IA). China has a population of 290 million experiencing different kinds of cardiovascular and cerebrovascular diseases, including hypertension in 270 million people, stroke in 7 million people, and myocardial infarction in 2.5 million people. One hundred fifty-nine million people are admitted to hospitals annually, and the costs on hospitalization in total and per capital are increased astronomically. In the last decade, the Chinese mortality rates of cardiovascular and cerebrovascular diseases are increased to 262 per 100 000 in urban and 296 per 100 000 in rural, respectively (Online Figure IB). The high mobility rate of China’s cardiovascular and cerebrovascular diseases can be mainly ascribed to the paucity of early diagnosis of vascular lesions and lack of effective control of risk factors. In addition, the prevalence of cardiovascular disease in China has their distinct characters. For example, the incidence of stoke in China is higher than that of myocardial infarction, and the mortality rate of cerebral hemorrhage is greatly higher than in the United States and other western countries. Secondly, diabetes mellitus has become a major public health problem in China. The age-standardized prevalence of total diabetes mellitus and prediabetes were 9.7% and 15.5% in population, respectively. Third, the hypertension has become a rapidly growing public health concern in China, more than half of the cardiovascular diseases are associated with hypertension. There is an urgent need to establish a national strategy for basic, translational, and clinical research in line with the Chinese population.Opportunities and Status Quo of Vascular Biology Research in ChinaWith the development of China’s economy, funds for scientific research are also increased rapidly. The National Natural Science Foundation of China (NSFC) and the Ministry of Science and Technology of China are the main funding agencies for vascular biology research in China. From 2007 to 2016, the NSFC and Ministry of Science and Technology of China allocated $159 million and $25 million research funding, respectively, for the studies in vascular disease. In 2009, the Department of Health Science of NSFC was further established as professional organization that funds the basic research of medicine in China. In recent years, it accepts a total of ≈50 000 grant applications annually. The main types of funded grants are classified into research-related projects and talent-oriented projects. In 2016, the number of vascular biology projects funded was 3.5× than that of 2007 (Figure [A]), with the total funding increased from $4 million in 2007 to $28 million in 2016 (Figure [B]). Meanwhile, the overall supporting rate elevated from 11.1% in 2007 to 27.9% in 2016 (Figure [C]).Download figureDownload PowerPointFigure. Grants from the National Natural Science Foundation of China (NSFC) for vascular biology and medicine during 2006 to 2015. A, The number of talent-oriented and research-related grants. B, The funding amounts of talent-oriented and research-related grants. C, The supporting rates of NSFC grants. The data were provided by NSFC. RMB indicates Renminbi.The research on vascular biology and vascular medicine in China is developing vigorously. In the past 10 years (2006–2015), Chinese scholars have published >18 000 research articles according to Web of Science statistics, searched with blood vessels, hypertension, and atherosclerosis as keywords. This accounts for ≈10% of the total number of relevant articles in the world, second only to the United States in number (Online Figure IIA). The number of articles on vascular research by Chinese scientists in 2015 was 6-fold than that in 2006 (Online Figure IIB). Moreover, China ranks the ninth place in the world with regard to the total number of annually publication citation in 10 years (Online Figure IIC), and the number of highly cited articles with top 1% citation in 2015 was >7× of that in 2006 (Online Figure IID). In 2011, the first China’s National Key Laboratory for Cardiovascular Disease was established based in Fuwai Hospital, Beijing. Moreover, there are dozens of cardiovascular key laboratories from the Ministry of Education and Ministry of Health and hundreds of cardiovascular research institutes nationwide (Online Table I). Dozens of professional societies, such as Society of Vascular Medicine, Circulation, and Atherosclerosis, were established.Morover, the Chinese government attaches great importance to the cultivation of young talent and strength in vascular biology and medicine research field. For example, there are at least 5 different kinds of talent funds from NSFC as shown in the Online Data Supplement. Moreover, the Ministry of Education of China has initiated the Yangtze River Scholar award, also known as the Cheung Kong Scholar award in 1998 to support the most distinguished professors in universities.In 2013, NSFC launched a special research program project on the mechanisms underlying vascular homeostasis and remodeling, with at least $30 million to be invested during the next 8 years. This is, by far, China’s largest research program on vascular diseases. This major research program encourages cross-disciplinary collaboration, and in the past 4 years, it has funded 124 scientists with a total of $20 million, with breakthrough results achieved in the areas of vascular injury, atherosclerosis, hypertension, vascular development and aging, pulmonary vascular diseases, and other fields. Since then, total 465 research articles were published supported by this program project, including 4 articles on nature and science and 42 articles on circulation, circulation research, and other American Heart Association journals. The representive main discoveries in vascular biology supported by this project are listed in the Online Data Supplement.ProspectiveManagement of vascular diseases has increasingly garnered the attention by Chinese government and the public. The major unsolved questions in this field involved 2 aspects. One is the mechanism of maintenance of vascular homeostasis and injury repair in response to environmental cue. As Chinese cardiovascular researchers, we also need to explore the underlying mechanisms for those distinct characters of cardiovascular disease in China, genetically and epigenetically. With the advance and development of stem cell research, nanotechnology, material science, 3D printing, etc, some major breakthrough will be achieved in the field in the near future. The other important issue is pathogenesis, prevention, and therapy of metabolic diseases and vascular complications. For Chinese scientists, metabolic vascular diseases become more urgent problem to solve because diabetes mellitus and metabolic syndrome have become a major public health problem in China.There is still a long way to go for China’s vascular biology and vascular medical research. For example, we still lack distinguished world-renowned scientists in the vascular field. Only one national cardiovascular key laboratory has been established to date. There is still a shortage of original studies with high impact, as well as multidisciplinary joint researches. The big gap between basic research and clinical application still exists. There is no loud Chinese voice and Chinese regimens in the international academic arena.However, we must acknowledge that there are advantages for the current Chinese cardiovascular biologists as well. China owns the largest cardiovascular patients resources and precious biological samples. During the past 20 years, many active Chinese researchers with overseas experience have returned to China under the support of governmental and institutional talent programs, such as One Hundred Talents Program initiated in 1994, and more recently, Thousand Young Talents Program launched in 2011 by the central government. In addition, the government-oriented input and encouragement of multidisciplinary collaborations are greatly increased in recent years. With the more highly motivated and talented interdisciplinary researchers are involved, the in-depth basic research on vascular biology and clinical translation will be dramatically accelerated, thereby making great contributions to the health of Chinese people.AcknowledgmentsWe thank Yuangui Zhu from National Natural Science Foundation of China and Wenying Yang, Yu Dong, and Jielan Ding from National Science Library, Chinese Academy of Sciences for the analysis of publications in the field of vascular research.Sources of FundingThis research was supported by funding from the National Natural Science Foundation of China (91539203 and 81220108004).DisclosuresNone.FootnotesThe opinions expressed in News & Views are not necessarily those of the editors or of the American Heart Association.The online-only Data Supplement is available with this article at http://circres.ahajournals.org/lookup/suppl/doi:10.1161/CIRCRESAHA.117.310839/-/DC1.Correspondence to Erdan Dong, MD, PhD, Department of Health Sciences, National Natural Science Foundation of China, Beijing, China. E-mail [email protected] Previous Back to top Next FiguresReferencesRelatedDetailsCited By Sun Y, Zhao Z, Zhang H, Li J, Chen J, Luan X, Min W and He Y (2020) The interaction of lead exposure and CCM3 defect plays an important role in regulating angiogenesis through eNOS/NO pathway, Environmental Toxicology and Pharmacology, 10.1016/j.etap.2020.103407, 79, (103407), Online publication date: 1-Oct-2020. Bolli R (2019) Ten Years at the Helm of Circulation Research, Circulation Research, 124:12, (1707-1717), Online publication date: 7-Jun-2019. Wang R, Wang Y, Wu J, Guo Y, Xiao H, Zhang Y and Ma K (2022) Resveratrol Targets AKT1 to Inhibit Inflammasome Activation in Cardiomyocytes Under Acute Sympathetic Stress, Frontiers in Pharmacology, 10.3389/fphar.2022.818127, 13 August 4, 2017Vol 121, Issue 4 Advertisement Article InformationMetrics © 2017 American Heart Association, Inc.https://doi.org/10.1161/CIRCRESAHA.117.310839PMID: 28775012 Originally publishedAugust 4, 2017 PDF download Advertisement SubjectsVascular BiologyVascular Disease

Characteristics and Trends in Clinical Trials of Cardiovascular Drugs in China from 2009 to 2021

The Changing Landscape of Drug Clinical Trials on Cardiometabolic Diseases in China, 2009–2021

Characteristics of High Risk People with Cardiovascular Disease in Chinese Rural Areas: Clinical Indictors, Disease Patterns and Drug Treatment

Analysis of clinical trials of new drugs in China as of 2019

Changes in Early-Phase Clinical Trials in China During 2013–2022: A Review

Cardiovascular Diseases in China: Current Status and Future Perspectives

Changes in clinical trials of cancer drugs in mainland China over the decade 2009-18: a systematic review

Chinese Clinical Trial Registry 13-year data collection and analysis: geographic distribution, financial support, research phase, duration, and disease categories

Current Status and Evaluation of Randomized Clinical Trials of Traditional Chinese Medicine in the Treatment of Cardiovascular Diseases

Analysis of clinical trials supported by foreign pharmaceutical industries in China

Overview of Registered Trials on the Chinese Clinical Trial Registry (Chictr)

Advances in clinical trials of diabetes drugs research in China, 2019 to 2021

Trends of Phase I Clinical Trials of New Drugs in Mainland China Over the Past 10 Years (2011–2020)

Development of clinical trials for non-small cell lung cancer drugs in China from 2005 to 2023

Chinese Basic Cardiovascular Research in Transition.

Analysis of Clinical Trials on Therapies for Prostate Cancer in Mainland China and Globally from 2010 to 2020

Pediatric Clinical Trials in Mainland China Over the Past Decade (From 2009 to 2020)

Characteristics and research status among clinical trials in cardio‐oncology by bibliometric and visualized analysis

Analysis ofclinical trials of rare disease drugsin China and abroad

Basic and Translational Vascular Research in China

Trends and disparities in China's cardiovascular disease burden from 1990 to 2019